Pre-made Cibisatamab biosimilar (Bispecific mAb with Domain Crossover, anti-CEACAM5;CD3E therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-104
Anti-CEACAM5;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cibisatamab, an investigational drug, is a bispecific antibody, which means it binds to two different proteins: one called CEACAM5 on the surface of some colorectal cancer cells and another on T cells called CD3.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CEACAM5;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover)|
|Format||Bispecific mAb with Domain Crossover|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Non-small cell lung cancer;Colorectal cancer|
|Conditions Discontinued||Solid tumours|